Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic

Author(s): Sumit Sharma, Sonali Batra, Saurabh Gupta*, Vivek K. Sharma, Md. Habibur Rahman and Mohammad Amjad Kamal

Volume 21, Issue 3, 2022

Published on: 08 March, 2021

Page: [228 - 234] Pages: 7

DOI: 10.2174/1871527320666210308113457

Price: $65

Abstract

Increasing reports of neurological symptoms in COVID-19 patient’s warrant clinicians to adopt and define the standardized diagnostic and managing protocols in order to investigate the linkage of neurological symptoms in COVID-19. Encephalitis, anosmia, acute cerebrovascular disease and ageusia are some of the emerging neurological manifestations which are reported in several cohort studies on hospitalized patients with COVID-19. Although the COVID-19 pandemic is primarily associated with infection of the respiratory tract system, but measures like lockdown and restricted physical movements to control the spread of this infection will certainly have neurobehavioural implications. Additionally, some of the patients with pre-existing neurological manifestations like epilepsy, Parkinson’s and Alzheimer’s disease are more prone to infection and demand extra care as well as improvised treatment. In this review, we have focused on the neurovirological clinical manifestations associated with the COVID-19 pandemic. Although the prevalence of neurovirological manifestations is rare increasing reports cannot be ignored and needs to be discussed thoroughly with respect to risk analysis and considerations for developing a management strategy. This also helps in defining the burden of neurological disorders associated with COVID-19 patients.

Keywords: Neurological manifestations, central nervous system, peripheral nervous system, encephalopathy, COVID-19, respiratory disease

« Previous Next »
Graphical Abstract

[1]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[2]
Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 2020; 296(2): E119-20.
[http://dx.doi.org/10.1148/radiol.2020201187] [PMID: 32228363]
[3]
Mao L. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. In: MedRxiv. 2020; 22.02: p. 20026500..
[4]
Armocida D, Palmieri M, Frati A, Santoro A, Pesce A. How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy. J Clin Neurosci 2020; 79: 231-6.
[http://dx.doi.org/10.1016/j.jocn.2020.07.007] [PMID: 33070902]
[5]
Sharma S, Lohan S, Murthy RS. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 2014; 40(7): 869-78.
[http://dx.doi.org/10.3109/03639045.2013.789051] [PMID: 23600649]
[6]
Li H, Xue Q, Xu X. Involvement of the nervous system in SARS-CoV-2 infection. Neurotox Res 2020; 38(1): 1-7.
[http://dx.doi.org/10.1007/s12640-020-00219-8] [PMID: 32399719]
[7]
Lau K-K, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004; 10(2): 342-4.
[http://dx.doi.org/10.3201/eid1002.030638] [PMID: 15030709]
[8]
Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G. COVID-19 infection and neurological complications: Present findings and future predictions. Neuroepidemiology 2020; 54(5): 364-9.
[http://dx.doi.org/10.1159/000508991] [PMID: 32610334]
[9]
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol 2020; 19(9): 767-83.
[http://dx.doi.org/10.1016/S1474-4422(20)30221-0] [PMID: 32622375]
[10]
Assari S. COVID-19 pandemic and neurological disease: A critical review of the existing literature. Hosp Pract Res 2020; 5(3): 81-6.
[PMID: 33094214]
[11]
Morfopoulou S, Brown JR, Davies EG, et al. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 2016; 375(5): 497-8.
[http://dx.doi.org/10.1056/NEJMc1509458] [PMID: 27518687]
[12]
Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: Underestimated damage to nervous system. Travel Med Infect Dis 2020; 36(5): 101642-2.
[http://dx.doi.org/10.1016/j.tmaid.2020.101642] [PMID: 32220634]
[13]
Ong W-Y. Effects of Antimalarial drugs on neuroinflammation-potential use for treatment of COVID-19-related neurologic complications. Mol Neurobiol 2020; 58(1) 106-17.
[PMID: 32897518]
[14]
Peluso R, Haase A, Stowring L, Edwards M, Ventura P. A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology 1985; 147(1): 231-6.
[http://dx.doi.org/10.1016/0042-6822(85)90246-6] [PMID: 2998068]
[15]
Desforges M, Le Coupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses 2019; 12(1): 14.
[http://dx.doi.org/10.3390/v12010014] [PMID: 31861926]
[16]
Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020; 16(11): 636-44.
[http://dx.doi.org/10.1038/s41582-020-0398-3] [PMID: 32839585]
[17]
Sonali B. COVID-19: An Insight on the third respiratory global emergency of the century. coronaviruses 2020; 1: 1-7.
[18]
Bénézit F, Le Turnier P, Declerck C, et al. RAN COVID Study Group. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infect Dis 2020; 20(9): 1014-5.
[http://dx.doi.org/10.1016/S1473-3099(20)30297-8] [PMID: 32304632]
[19]
Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awarthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatol Ther 2020; 33(4): e13591.
[20]
Wong G, Qiu X, Bi Y, et al. More challenges from ebola: Infection of the central nervous system. j infect dis 2016; 214(Suppl. 3): S294-6.
[http://dx.doi.org/10.1093/infdis/jiw257] [PMID: 27707893]
[21]
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020; 413: 116832.
[http://dx.doi.org/10.1016/j.jns.2020.116832] [PMID: 32299017]
[22]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[23]
Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020; 5(3): 279-84.
[http://dx.doi.org/10.1136/svn-2020-000431] [PMID: 32616524]
[24]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[25]
Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to- moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277(8): 2251-61.
[http://dx.doi.org/10.1007/s00405-020-05965-1] [PMID: 32253535]
[26]
Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci 2020; 35(18): e174.
[http://dx.doi.org/10.3346/jkms.2020.35.e174] [PMID: 32383370]
[27]
Bhaskar S, Bradley S, Israeli-Korn S, et al. Chronic neurology in COVID-19 era: Clinical considerations and recommendations from the reprogram consortium. front neurol 2020; 11(664): 664.
[http://dx.doi.org/10.3389/fneur.2020.00664] [PMID: 32695066]
[28]
Garg RK. Spectrum of neurological manifestations in Covid-19: A review. Neurol India 2020; 68(3): 560-72.
[http://dx.doi.org/10.4103/0028-3886.289000] [PMID: 32643664]
[29]
DeMaagd G, Philip A. Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P&T 2015; 40(8): 504-32.
[PMID: 26236139]
[30]
Prasad S, Holla VV, Neeraja K, et al. Parkinson’s disease and COVID-19. Mov Disord 2020; 35(6): 912-4.
[http://dx.doi.org/10.1002/mds.28088] [PMID: 32304118]
[31]
Bird E. What are the neurological complications of COVID-19? In: Medical News Today. 2020.
[32]
Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. am j geriatr psychiatry 2020; 28(7): 712-21.
[http://dx.doi.org/10.1016/j.jagp.2020.04.010] [PMID: 32331845]
[33]
Jacob S, Muppidi S, Guidon A, et al. International MG/COVID-19 Working Group. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 2020; 412: 116803.
[http://dx.doi.org/10.1016/j.jns.2020.116803] [PMID: 32247193]
[34]
COVID-19: FAQs for Sleep Clinicians 2020.
[35]
Rodriguez T. Critical insights into the neurologic effects of COVID-19. In: Neurology Advisor. 2020.
[36]
Chen X, Laurent S, Onur OA, et al. A systematic review of neurological symptoms and complications of COVID-19. J Neurol 2020; 268(2): 392-402.
[37]
Barišić A. Conceived in the covid-19 crisis: impact of maternal stress and anxiety on fetal neurobehavioral development. J Psychosom Obstet Gynecol 2020; 41: 246.
[38]
Cuffaro L, Di Lorenzo F, Bonavita S, Tedeschi G, Leocani L, Lavorgna L. Dementia care and COVID-19 pandemic: a necessary digital revolution. Neurol Sci 2020; 41(8): 1977-9.
[39]
Kuroda N. Epilepsy and COVID-19: Associations and important considerations. Epilepsy Behav 2020; 108: 107122.
[http://dx.doi.org/10.1016/j.yebeh.2020.107122] [PMID: 32361677]
[40]
Sohal S, Mansur M. COVID-19 Presenting with Seizures. IDCases 2020; 20: e00782.
[http://dx.doi.org/10.1016/j.idcr.2020.e00782] [PMID: 32363146]
[41]
De Felice FG, Tovar-Moll F, Moll J, Munoz DP, Ferreira ST. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system. Trends Neurosci 2020; 43(6): 355-7.
[http://dx.doi.org/10.1016/j.tins.2020.04.004] [PMID: 32359765]
[42]
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20(4): 400-2.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID: 32113509]
[43]
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 2019; 10(2847): 2847.
[http://dx.doi.org/10.3389/fimmu.2019.02847] [PMID: 31849996]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy